AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2702284&ei=n4aaUvD9OdO60AGuJw&usg=AFQjCNFn8-mV6cHwLm-hv5y-a7uZvFdgKQ
FDA Halts Trials Of Amgen Inc Drug In Children, Cites Death-Reuters
Tuesday, 26 Feb 2013 01:10pm EST
Reuters reported that The U.S. Food and Drug Administration said, it has stopped all pediatric clinical trials of Amgen Inc's Sensipar after the death of a 14-year-old patient taking part in a study of the drug. Sensipar, which is approved for adults, is used to lower dangerously high calcium levels in the blood. The agency said it was collecting information on the circumstances of the teenager's death. It said it does not know if the Amgen drug had any role in the death.Â 
